Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | DUT | P33316 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876097 | 0.85 | BACE1 (0.31) | MAPTHPGDBACE1DUT | |
| SCHEMBL2948345 | 0.85 | KDM4E (0.34) | MAPTHPGDBTN3A1BACE1GAA | |
| SCHEMBL9163997 | 0.83 | BACE1 (0.30) | MAPTHPGDBACE1 | |
| SCHEMBL2163046 | 0.83 | TSHR (0.40) | MAPTHPGDBTN3A1BACE1 | |
| SCHEMBL7128084 | 0.82 | BTN3A1 (0.30) | BTN3A1 | |
| SCHEMBL7748875 | 0.81 | — | — | |
| SCHEMBL8451321 | 0.81 | — | — | |
| SCHEMBL2904267 | 0.81 | BTN3A1 (0.31) | BTN3A1 | |
| SCHEMBL22033623 | 0.81 | — | — | |
| SCHEMBL2720155 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4735449-A1 | TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE | OmniAB, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116888-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | NOVARTIS AG (CH) | 2026-04-30 | — | — | US | disclosed |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20250376469-A1 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| US-20250320189-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-10-16 | — | — | US | disclosed |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-10-14 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| EP-1846375-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-10-24 | — | — | EP | disclosed |
| EP-1841727-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006067430-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067423-A1 | GLYCINE TRANSPORT INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-5607928-A | Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives | ZENECA LIMITED (GB) | 1997-03-04 | — | — | US | disclosed |
| EP-0695753-A1 | Carbapenem derivatives containing a bicyclic substituent, process for their preparation, and their use | ZENECA LIMITED (GB) | 1996-02-07 | — | — | EP | disclosed |
| EP-0282492-A1 | ANTIMICROBIAL N-ACYL-2-AZETIDINONES | THE UPJOHN COMPANY (US) | 1988-09-21 | — | — | EP | disclosed |
| EP-0232017-A1 | Antimicrobial N-acyl-2-azetidinones | THE UPJOHN COMPANY (US) | 1987-08-12 | — | — | EP | disclosed |
| WO-1987004429-A1 | ANTIMICROBIAL N-ACYL-2-AZETIDINONES | THE UPJOHN COMPANY (US) | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320189-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM2, TRPM6 | MAPT 1361/4885HPGD 952/4885BTN3A1 740/4885 |
| US-12441731-B2 | Pyrazolopyrimidine compounds and uses thereof | ALK, FGFR1, FGFR2 | MAPT 4190/4885HPGD 2197/4885BTN3A1 4602/4885 |
| US-20260116888-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK4, CCNC, CDK6 | MAPT 4239/4885HPGD 2637/4885BTN3A1 3386/4885 |
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM5, TRPM4 | MAPT 2757/4885HPGD 692/4885BTN3A1 938/4885 |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | MAPT 2020/4885HPGD 585/4885BTN3A1 667/4885 |
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | MAPT 124/4885HPGD 682/4885BTN3A1 3357/4885 |
| US-20250376469-A1 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM4, TRPM2 | MAPT 1938/4885HPGD 714/4885BTN3A1 853/4885 |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCR2, CXCR1 | MAPT 3767/4885HPGD 1229/4885BTN3A1 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.